Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment
Article Details
Journal Info
New England Journal of Medicine
Massachusetts Medical Society
Authors (13)
Sean Wharton
Louis J. Aronne
Comprehensive Weight Control Center, Division of Endocrinology, Diabetes, and Metabolism, Weill Cornell Medicine, New York
Adam Stefanski
Eli Lilly, Indianapolis
Nasreen F. Alfaris
Obesity, Endocrine, and Metabolism Center, King Fahad Medical City, Riyadh, Saudi Arabia
Andreea Ciudin
Endocrinology and Nutrition Department, Hospital Universitari Vall d’Hebron, Barcelona
Koutaro Yokote
Bruno Halpern
Obesity Center, Nove de Julho Hospital, São Paulo
Alpana P. Shukla
Comprehensive Weight Control Center, Division of Endocrinology, Diabetes, and Metabolism, Weill Cornell Medicine, New York
Chunmei Zhou
Eli Lilly, Indianapolis
Lisa Macpherson
Eli Lilly, Indianapolis
Sheryl E. Allen
Eli Lilly, Indianapolis
Nadia N. Ahmad
Suzanne R. Klise
Eli Lilly, Indianapolis